Publications by authors named "G Oldani"

Rosai-Dorfman disease (RDD) is a nonmalignant disease of histiocyte proliferation. RDD usually presents with painless cervical lymphadenopathy, although extranodal involvement can occur. Cardiac involvement was reported in <0.

View Article and Find Full Text PDF
Article Synopsis
  • Maternal obesity has been linked to a higher risk of hepatocellular carcinoma (HCC) in offspring, and this study explores the mechanisms behind this connection.
  • Female mice were fed either a high-fat diet or a normal diet, and their offspring were studied for liver health and tumor development after being induced with HCC.
  • Results showed that offspring from obese mothers had more liver diseases and tumors, linked to changes in gut microbiome, suggesting that gut health may play a critical role in developing these conditions.
View Article and Find Full Text PDF

Background And Aims: Non-alcoholic fatty liver disease (NAFLD) is one of the leading cause of hepatocellular carcinoma (HCC). This association is supported by the translocation of bacteria products into the portal system, which acts on the liver through the gut-liver axis. We hypothesize that portosystemic shunting can disrupt this relationship, and prevent NAFLD-associated HCC.

View Article and Find Full Text PDF

Chronic liver disease (CLD) is a serious condition where various toxins present in the blood affect the brain leading to type C hepatic encephalopathy (HE). Both adults and children are impacted, while children may display unique vulnerabilities depending on the affected window of brain development.We aimed to use the advantages of high field proton Magnetic Resonance Spectroscopy (H MRS) to study longitudinally the neurometabolic and behavioural effects of Bile Duct Ligation (animal model of CLD-induced type C HE) on rats at post-natal day 15 (p15) to get closer to neonatal onset liver disease.

View Article and Find Full Text PDF

Objective: Obesity and associated liver disease are a growing public health concern. Pharmacological agents to treat non-alcoholic fatty liver disease are limited. FGF21, a hormone secreted by the liver and potent metabolic modulator, is a promising therapeutic target for this indication with several analogs currently in clinical development.

View Article and Find Full Text PDF